Navigation Links
PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
Date:7/27/2009

SOUTH PLAINFIELD, N.J., July 27 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 2 clinical trial of PTC299 in adult patients with neurofibromatosis type 2 (NF2), a rare genetic disorder that causes the development of non-malignant brain tumors. PTC299 is a novel, orally administered investigational new drug that is designed to selectively block tumor-related vascular endothelial growth factor (VEGF). With its novel mechanism of action, PTC299 has the potential to meet significant unmet medical need in NF2 and other conditions resulting from the overexpression of VEGF.

(Logo:http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

VEGF plays a critical role in the formation of new blood vessels or angiogenesis and its suppression has been shown to decrease tumor size and improve hearing in some patients with NF2. PTC299 selectively blocks the tumor-related production of VEGF, while sparing the physiological VEGF expression necessary to maintain the growth and function of normal blood vessels. Patients with NF2 typically develop tumors that compress the auditory nerves, often leading to deafness and problems with balance. If unchecked, NF2-related tumors may eventually damage other cranial nerves and the brainstem, and become life-threatening. Current standard treatments for NF2-related tumors include surgery and radiation therapy. However, a study conducted at Massachusetts General Hospital and recently published in the New England Journal of Medicine validates the potential of anti-angiogenesis therapies for NF2 patients.

"The development of PTC299 for the treatment of NF2 is noteworthy for patients, especially following our recent findings that an angiogenesis inhibitor improved hearing and led to tumor shrinkage in some patients," said Sco
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
2. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
3. Cell Therapeutics, Inc. Announces Exercise of Overallotment
4. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
5. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
7. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
8. Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens
9. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
10. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
11. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... (August 22nd), in the scientific journal PLoS ... establish the effect of serotonin on sensitivity to ... optical techniques., "Serotonin is a small molecule known ... brain functions, from the control of sleep and ... This neurotransmitter is also popularly thought to contribute ...
(Date:8/22/2014)... 22, 2014 Research and Markets ... China Gel Permeation Chromatography (GPC) Industry Report 2014" ... and China Gel Permeation Chromatography (GPC) Industry Report is ... of the global gel permeation chromatography industry with a ... a basic overview of the industry including definitions, classifications, ...
(Date:8/22/2014)... Greenville, SC (PRWEB) August 22, 2014 ... that indisputable acknowledgement is a national disgrace. Furthermore, ... part in establishing the current, deplorable state of ... outlined "5 great mistakes," to merely serve as ... convey the extent of colossal failure(s) that have ...
(Date:8/21/2014)... 2014 2014 Deep Research ... a professional and in-depth research report on ... basic Seaweed Fertilizer information, including Seaweed Fertilizer ... as well as industry overview. This research ... market as well as global industry analysis ...
Breaking Biology Technology:From happiness to pain: Understanding serotonin's function 2Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 25 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3
... Inc., a medical device,company that has developed a ... announced today that they have successfully raised $1.4,million ... Chief,Executive Officer, Clark Adams stated, "Valor,s Board and ... will be used to complete,clinical trials needed for ...
... 6 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... extracellular matrix for the drug delivery,endocrinology, oncology, and ... and nine months ended September 30, 2008., ... and I am,pleased with the initiation of our ...
... 6 NutraCea (OTC Bulletin Board:,NTRZ), a world ... and,technology announced today that it has appointed Olga ... Todd Crow, in accordance with,his previously announced intentions, ... a consulting and advisory capacity., Ms. Hernandez-Longan ...
Cached Biology Technology:Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 6Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 7Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 8NutraCea Appoints New Chief Financial Officer 2
(Date:8/22/2014)... French . NAIROBI (22 ... soils looming as a major threat to food security across ... the last five years, 1.7 million African farmers in 13 ... hectares and helped them double or even triple crop yields. ... in Africa (AGRA) focuses on intensive efforts initiated five years ...
(Date:8/22/2014)... 2014 Diabetes affects nearly 10 percent of ... diabetics: constant finger pricking to test blood glucose ... reports the development of a protein that could ... for diabetes patients. In the American Chemical Society,s ... shows off her "designer protein" that could eventually ...
(Date:8/22/2014)... MD FASEB MARC (Maximizing Access to Research Careers) ... FASEB Grant Writing Seminar & Practical Exercises Workshop which ... Bethesda, Maryland from August 25-26, 2014. These awards ... and research scientists from underrepresented groups in the the ... This year MARC conferred 11 awards totaling $20,350. , ...
Breaking Biology News(10 mins):Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4
... light on the causes of Parkinson,s disease, researchers report that ... mitochondria. A shutdown in fuel can have devastating effects on ... energy despite making up only 2 percent of body weight. ... FDA approved drugs early on may prevent or delay the ...
... CAMBRIDGE, Mass. -- By creating a better way to ... with MIT,s Picower Institute for Learning and Memory and the ... synapse formation. These studies could also help further understanding of ... and Fragile X syndrome. The study will appear in the ...
... their dosages may be standardized, but not every patient ... personal genetic characteristics of individuals and populations can explain ... not another, so medical researchers are adopting the new ... lab is leading the way. Dr. Noam ...
Cached Biology News:In Parkinson's disease, brain cells abandon mitochondria, researchers report 2In Parkinson's disease, brain cells abandon mitochondria, researchers report 3MIT researchers develop a better way to see molecules at work in living brain cells 2An X-ray for your genes 2
... 1) Persistent Analysis Environment 2) Dot ... etc. 3) Software Compensation 4) Cell ... Kinetics Platform 7) Intelligent batch generation of ... smoothing 9) Single drag-and-drop operations to perform ...
... PEP-174 is a 12 amino acid synthetic peptide whose sequence ... this peptide is (amino to carboxy terminus): C - ... S - Q - V - A - P - ... and control experiments with the polyclonal antibody that reacts with ...
... Analytical System more than doubles the benefits ... The fast analysis cycles of the standard ... 100% in tandem mode. Difficult separations are ... backflush or heartcut configurations, on-line sample preparation ...
... kit are prepared with pure chemicals according ... Isolation Kit is designed to isolating intact ... easy way. One kit is consisted of ... mitochondria from 10 20 g tissue ...
Biology Products: